Repairing the parkinsonian brain with neurotrophic factors

Trends Neurosci. 2011 Feb;34(2):88-100. doi: 10.1016/j.tins.2010.11.001. Epub 2010 Dec 7.

Abstract

No therapy exists to slow down or prevent Parkinson's disease (PD), a debilitating neurodegenerative disorder. Neurotrophic factors (NTFs) emerged as promising disease-modifying agents in PD and are currently under clinical development. We argue that efforts in three research areas must converge to harness the full therapeutic power of NTFs. First, the physiological roles of NTFs in aging dopaminergic neurons must be comprehensively understood. Second, the mechanisms underlying the neuroprotective, neurorestorative and stimulatory effects of NTFs on diseased neurons need to be defined. Third, improved brain delivery of NTFs and new ways to stimulate NTF signaling are required to achieve clinical benefits. In this review, we discuss progress in these areas and highlight emerging concepts in NTF biology and therapy.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Brain / pathology*
  • Brain / physiology
  • Clinical Trials as Topic
  • Dopamine / metabolism
  • Humans
  • Nerve Growth Factors / genetics
  • Nerve Growth Factors / metabolism
  • Nerve Growth Factors / therapeutic use*
  • Nerve Regeneration / physiology*
  • Neurodegenerative Diseases / pathology
  • Neurodegenerative Diseases / physiopathology
  • Neurodegenerative Diseases / therapy*
  • Neurons / physiology
  • Parkinson Disease / pathology
  • Parkinson Disease / physiopathology
  • Parkinson Disease / therapy*
  • Signal Transduction / physiology

Substances

  • Nerve Growth Factors
  • Dopamine